However, limited GIP-induced acute postprandial release of cytokines may represent a physiological response required for healthy adipose tissue function [14]
N Engl J Med 392(6):612615 Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
doi: 10.1017/S0022215100091374
2 The GLP1R weight loss finding replicated in the All of Us cohort of 4,855 people (P = 0.001), but didnt replicate in the UK Biobank, though the authors note that statistical power for replication in that cohort was low